3-氨基-4-苯基-1H-吡唑 | 5591-70-8

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 3-氨基-4-苯基-1H-吡唑
• 中文别名: 4-苯基-1H-吡唑-3-胺；3-氨基-4-苯基吡唑
• 英文名称: 4-phenyl-1H-pyrazol-5-amine
• 英文别名: 5-Amino-4-phenyl-pyrazol；5-amino-4-phenylpyrazole；5-amino-4-phenyl-1H-pyrazole
• CAS: 5591-70-8
• 化学式: C₉H₉N₃
• mdl: MFCD01693715
• 分子量: 159.191
• InChiKey: QEHKQNYBBLCFIJ-UHFFFAOYSA-N

物化性质

• 熔点：
  170-173℃
• 沸点：
  394.4±30.0 °C(Predicted)
• 密度：
  1.238±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  在常温常压下，该物质保持稳定。

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.7
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险品运输编号：
  NONH for all modes of transport
• WGK Germany：
  3
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  请将药品存放在避光、阴凉且干燥的地方，并密封保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Amino-4-phenyl-1h-pyrazole
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Amino-4-phenyl-1h-pyrazole
CAS number: 5591-70-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C9H9N3
Molecular weight: 159.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-氨基-4-苯基-1H-吡唑 在 盐酸 、 sodium nitrite 作用下， 以 水 为溶剂， 以81%的产率得到3-diazo-4-phenylpyrazolium chloride
  参考文献：
  名称：

  Joshi; Pathak; Garg, Journal of the Indian Chemical Society, 1983, vol. 60, # 11, p. 1074 - 1076

  摘要：

  DOI：
• 作为产物：
  描述：

  3-Nitro-4-phenyl-pyrazol 在 乙醇 、 铂 作用下， 生成 3-氨基-4-苯基-1H-吡唑
  参考文献：
  名称：

  The Condensation of Diazo Compounds with Nitroölefins. II. 3-Bromo- and 3-Nitropyrazoles

  摘要：

  DOI：

  10.1021/ja01154a051

文献信息

• β-Amination of Saturated Nitriles through Palladium-catalyzed Dehydrogenation, 1,4-Addition, and Re-dehydrogenation
  作者：Satoshi Ueno、Ryohei Maeda、Shohei Yasuoka、Ryoichi Kuwano

  DOI：10.1246/cl.2013.40

  日期：2013.1.5

  Amination at the β-position of 2-arylpropionitriles through catalytic dehydrogenation occurred by using [PdCl2(PMe3)2] catalyst and bromobenzene. This is the first catalytic reaction involving the direct dehydrogenation of saturated nitriles.

  在[PdCl2(PMe3)2]催化剂和溴苯的作用下，通过催化脱氢反应实现了2-芳基丙腈分子中β位上的氨化。这是首次涉及饱和腈直接脱氢的催化反应。
• HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK
  申请人：McCall John M.

  公开号：US20120277224A1

  公开（公告）日：2012-11-01

  Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

  本文披露了新的杂环化合物和组合物，以及它们作为药物治疗疾病的应用。还提供了抑制PAS激酶（PASK）在人类或动物主体中活性的方法，用于治疗疾病，如糖尿病。
• Design of Potent, Selective, and Orally Bioavailable Inhibitors of Cysteine Protease Cathepsin K
  作者：Francis X. Tavares、Virginia Boncek、David N. Deaton、Anne M. Hassell、Stacey T. Long、Aaron B. Miller、Alan A. Payne、Larry R. Miller、Lisa M. Shewchuk、Kevin Wells-Knecht、Derril H. Willard、Lois L. Wright、Hui-Qiang Zhou

  DOI：10.1021/jm030373l

  日期：2004.1.1

  resorption has been attributed to cathepsin K, a cysteine protease of the papain family that is abundantly and selectively expressed in osteoclast. Inhibition of cathepsin K could potentially be an effective method to prevent osteoporosis. Structure-activity studies on a series of reversible ketoamides based inhibitors of cathepsin K have led to identification of potent and selective compounds. Crystallographic

  破骨细胞介导的骨基质吸收归因于组织蛋白酶K，这是木瓜蛋白酶家族的半胱氨酸蛋白酶，在破骨细胞中大量表达并选择性表达。抑制组织蛋白酶K可能是预防骨质疏松症的有效方法。对一系列基于组织蛋白酶K的可逆性基于酮酰胺的抑制剂的结构活性研究已导致鉴定出有效的和选择性的化合物。晶体学研究已经洞悉了这些抑制剂的结合方式。首先合成了一系列具有不同P1部分的酮酰胺，以找到适合于半胱氨酸蛋白酶组织蛋白酶K的S1亚位的最佳基团。通过适当的P1基团，在P'区合成了各种杂环类似物研究它们的空间和电子效应。在探索这些P'杂环变异的过程中，与其他高度同源的半胱氨酸蛋白酶（包括组织蛋白酶L，S和V）相比，具有出色的选择性。某些组织蛋白酶K抑制剂在大鼠中的良好药代动力学特性使其适合于在大鼠体内进行评估。啮齿动物骨质疏松模型。在TPTX大鼠模型中，代表性的组织蛋白酶K抑制剂可减轻PTH刺激的高钙血症。这些抑制剂为发现预防和治疗骨质疏松症的新疗法提供了可行的先导系列
• Copper-Catalyzed<i>N</i>-Aryl-β-enaminonitrile Synthesis Utilizing Isocyanides as the Nitrogen Source
  作者：Seoksun Kim、Soon Hyeok Hong

  DOI：10.1002/adsc.201400973

  日期：2015.3.23

  A novel synthetic protocol for N‐aryl‐β‐enaminonitriles, which are useful building blocks for heterocycle synthesis, was developed using isocyanides as the nitrogen source. Using copper‐catalyzed one‐step reactions between isocyanides and benzyl cyanides under mild conditions, diverse N‐aryl‐β‐enaminonitriles could be synthesized in excellent yields and with high atom‐efficiency. N‐Alkyl‐β‐enaminonitriles

  使用异氰化物作为氮源，开发了一种新的N-芳基-β-烯胺腈合成方案，这是杂环合成的有用组成部分。使用异腈和苄基氰之间铜催化的单步反应在温和的条件，不同的下ñ -芳基- β-enaminonitriles可以以优良产率和具有高原子效率来合成。N-烷基-β-氨基腈也以高收率合成。基于机理研究和先前的报道，提出了一种涉及亚氨基-铜-铜中间体的机理。此外，我们证明了合成的N芳基-β-氨基腈可用于合成β-酮腈化合物和3-氨基吡唑。
• [EN] APELIN RECEPTOR AGONISTS AND METHODS OF USE THEREOF<br/>[FR] AGONISTES DU RÉCEPTEUR DE L'APELINE ET LEURS MÉTHODES D'UTILISATION
  申请人：SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST

  公开号：WO2019032720A1

  公开（公告）日：2019-02-14

  Provided herein are agonists of the apelin receptor for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions.

  本文提供了用于治疗疾病的阿普林受体激动剂。本文披露的化合物对于治疗一系列心血管、肾脏和代谢状况是有用的。